PTC Therapeutics (PTCT) is in focus after a special call highlighted the expected completion of the ST-920 approval process in Q4 2026, supported by favorable Phase 1/2 STAAR renal and safety data.

Despite the positive tone of the ST-920 update, PTC Therapeutics’ recent share price has eased. The 1-day share price return is 4.28% and the 1-month share price return shows a decline of 10.17%, although the 1-year total shareholder return of 44.15% and 3-year total shareholder return of 80.82% point to stronger momentum over a longer horizon.

If this regulatory milestone has you rethinking growth opportunities in healthcare, it could be a good moment to scan other potential ideas through our healthcare AI stock list, starting with 41 healthcare AI stocks

PTC Therapeutics now trades below both analyst targets and some intrinsic value estimates, even after the recent pullback. Is the discount a sign that the market is being overly cautious about execution and profitability risks?

Most Popular Narrative: 27.2% Undervalued

PTC Therapeutics last closed at $70.52, while the most widely followed narrative sets fair value near $96.93. That gap frames how some analysts are thinking about the rare disease portfolio and pipeline today.

With the recent broad approvals of Sephience in both the U.S. and Europe for PKU (inclusive of all age groups and subtypes), PTC is positioned to rapidly capture substantial market share in a high-value rare disease segment, directly leveraging the increased global willingness to pay for medicines addressing unmet needs, driving future revenue growth and potentially accelerating the path to profitability.

Curious what needs to happen for that kind of fair value to stack up? Revenue forecasts, margin expansion and future earnings multiples all sit at the center of this narrative. Want to see which assumptions really move the dial on PTC Therapeutics?

Result: Fair Value of $96.93 (UNDERVALUED)

However, PTC Therapeutics still faces key risks, including heavy reliance on a small group of products and ongoing losses that could force more dilutive funding if launches disappoint.

Another View on PTC Therapeutics’ Valuation

The first narrative leans on detailed forecasts for PTC Therapeutics and treats the stock as undervalued against future earnings and analyst price targets. Yet the current P/S ratio of 5.8x is higher than an estimated fair ratio of 4.8x, which points to valuation risk if sentiment cools.

Relative to the wider US Biotechs industry average P/S of 11.6x and a peer average of 10.6x, PTC Therapeutics looks cheaper on sales, even though our fair ratio suggests the market could still move closer to 4.8x. How much weight do you want to give to this mixed signal on price versus fundamentals?

Next Steps

The mix of opportunity and concern around PTC Therapeutics is clear. Act while the details are fresh in your mind and weigh both sides through 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond PTC Therapeutics?

If PTC Therapeutics has you thinking more broadly about opportunities, now is the time to widen your view and line up your next few candidates.

• Target potential upside by scanning screener containing 19 high quality undiscovered gems that the market may not be paying full attention to yet.
• Prioritize resilience by reviewing 79 resilient stocks with low risk scores that score well on downside protection and stability.
• Strengthen your core holdings by assessing companies in the solid balance sheet and fundamentals stocks screener (50 results) that pair financial robustness with fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.